Empowering Precision in PH Care

The PH Network provides advanced insights and product information to support healthcare professionals in improving care for patients with PH, particularly those with PAH.

Welcome to the PH Network

Pulmonary arterial hypertension (PAH) is a rare, progressive, and potentially life-threatening disease that warrants timely intervention.^1,2 We recognize that modern management goes  far beyond symptomatic improvement — it demands a deep understanding of pathophysiology, and individualized and prompt management.^2,3 This platform is designed for clinicians, researchers, and care teams to explore: 

Innovative treatment strategies like upfront triple therapy
Comprehensive support for intravenous and subcutaneous Treprostinil
Practical infusion solutions and patient-centric care
Scientific insights from major congresses
Collaborative networks to foster shared learning

Explore key areas of the PH Network

Treprostinil Product Resources

Access clinical guidance, dosing tools, stability data, and integrated care models for delivering parenteral prostacyclin therapy effectively. Learn how Treprostinil impacts disease progression and increases long-term patient survival by targeting multiple aspects of the prostacyclin pathway.^2,4

Visit the Treprostinil Product Portal

Clinician talks with a male patient seated on an exam table while a heart ultrasound image is displayed on a monitor.

PAH Research  & Scientific Highlights

From real-world data to controlled trials, get in touch with evidence that’s shaping modern PAH therapy. Our research section offers brief summaries, full-text links, and highlights of research in PH with a focus on PAH.

Explore Research & Updates

Clinician listens to a patient’s chest with a stethoscope during a routine exam.

Congress Highlights

Can’t attend every session? No problem. We distill the key messages from top PAH congresses — so you can catch up on clinical trials, therapeutic updates, and emerging innovations in PAH.

View Congress Highlights

Shaping the Future

Learn more about leading experts who share insights about clinical challenges. Leverage their insights to advance your clinical approach.

Meet the Experts

Doctor reviews information on a clipboard while speaking with a patient in a medical office.

Treprostinil is indicated for the treatment of idiopathic or heritable pulmonary arterial hypertension (PAH) to improve exercise tolerance and symptoms of the disease in patients classified as New York Heart Association (NYHA) functional class III.

Prescribing information for Treprostinil can be found here.

References: 
1. Boucly A, et al. Presse Med 2023;52:104168; 2. Boucly A, et al. Am J Respir Crit Care Med 2021;204:842–854; 3. Mouratoglou SA, et al. Int J Cardiol Congenit Heart Dis 2025;21:100594; 4. Kolb M, et al. Adv Ther 2022;39:3881–3895.  

Image Credit:
Hero Image: “Pulmonary arterial changes suggestive of pulmonary hypertension in association with pulmonary veno-occlusive disease (PVOD) – Case 269” by Yale Rosen, licensed under CC BY-SA 2. Source: Wikimedia Commons.